Pulmonx
Redwood City, California, United States · Biotechnology, Health Care, Other
Pulmonx Corporation is a global leader in minimally invasive treatments for lung disease. The company has achieved major milestones including the execution of multiple randomized controlled trials, widespread regulatory approval and reimbursement, a successful IPO, and commencement of U.S. commercialization.
Key facts
- Headquarters
- Redwood City, California, United States
- Employees
- 280
- Industries
- Biotechnology, Health Care, Other
- Status
- Public (LUNG)
- Website
- pulmonx.com
- Company page
Recent activity at Pulmonx
- : SEC 8-K (1.01): On March 2, 2026, Pulmonx Corporation entered into a Credit Agreement and Guaranty with Perceptive Credit Holdings V, LP, establishing a senior secured term loan facility totaling up to $60.0 million. The Company initially borrowed $40.0 million on the closing date, with the potential for additional borrowing based on revenue milestones. The Loan Facility matures on March 2, 2031, and includes an interest rate structure tied to SOFR with a minimum rate. An upfront fee of $750,000 was paid at the closing. This agreement is significant for Pulmonx as it provides critical funding needed for ongoing operations and future growth objectives.
- : SEC 8-K (2.02): On March 4, 2026, Pulmonx Corporation announced its financial results for the fourth fiscal quarter and the full year ended December 31, 2025. This release highlights the Company’s financial performance and provides a detailed breakdown of revenues, expenses, and net income. The announcement serves as a crucial update for investors regarding Pulmonx's financial health and operational efficiency over the past fiscal year. The results were disclosed through a press release, which is attached as Exhibit 99.1.
- : Pulmonx Appoints Derrick Sung as Chief Operating Officer and Chief Financial Officer, Reappoints Glen French as President and Chief Executive Officer
- : SEC 8-K (5.02):
- : Pulmonx Corp
- : Pulmonx Corp
Pulmonx funding history
| Date | Round | Amount |
|---|---|---|
| Apr 2019 | Venture | $65.1M |
| Apr 2017 | Venture | $50.0M |
Leadership
- CHARLES CHON, Director
- OERN STUGE, Director
- DANA JR, Director
- STAFFAN LINDSTRAND, Director
- MICHAEL MATLY, Director
- STEPHEN SALMON, Director
- RODNEY M.D., Director
- RICH FERRARI, Director
- GLENDON FRENCH, Executive Officer, Director
- Derrick Sung, Chief Financial Officer
- Glen French, Chief Executive Officer
- LAUREN CRISTINA, Executive Officer
Verified email and direct lines for Pulmonx’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Pulmonx files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Pulmonx in the news
- Pulmonx to Report Third Quarter 2026 Financial Results on October 27, 2026 - Yahoo Finance (Oct 13, 2026)
- American Lung Association Campaign Shines Spotlight on Endobronchial Valves for Advanced COPD/Emphysema - American Lung Association (Dec 16, 2022)
- Pulmonx Reports Second Quarter 2026 Financial Results - Yahoo Finance (Jul 29, 2026)
- Pulmonx brings back former CEO amid leadership shakeup - Investing.com (Oct 27, 2025)
- Zephyr Endobronchial Valves One Step Closer to FDA Approval - respiratory-therapy.com (Nov 10, 2023)
- Helping patients breathe easier, Atlantic Health System offers breakthrough respiratory treatment - WRNJ Radio (Sep 11, 2024)
- Pulmonx Corporation Announces Participation in Upcoming Investor Conferences | LUNG Stock News - Quiver Quantitative (Aug 26, 2025)
- Pulmonx announces FDA approval of Zephyr Endobronchial Valve to treat severe emphysema - News-Medical (Jun 30, 2018)
Companies similar to Pulmonx
- Nurix Therapeutics · Biotechnology, Health Care, Other
- Venus Concept Inc. · Biotechnology, Health Care, Other
- Akoya Biosciences · Biotechnology, Health Care, Other
- SRx Health Solutions · Biotechnology, Health Care, Other
- IM Cannabis Corp · Biotechnology, Health Care, Other
About Pulmonx: questions and answers
What does Pulmonx do?
Pulmonx Corporation is a global leader in minimally invasive treatments for lung disease. The company has achieved major milestones including the execution of multiple randomized controlled trials, widespread regulatory approval and reimbursement, a successful IPO, and commencement of U.S. commercialization.
Where is Pulmonx headquartered?
Pulmonx is headquartered in Redwood City, California, United States.
How many employees does Pulmonx have?
Pulmonx has about 280 employees.
Has Pulmonx raised funding?
Yes. Fundz has recorded 2 funding events for Pulmonx. The most recent, $65.1M, was in Apr 2019.
Who leads Pulmonx?
Glen French is a Chief Executive Officer at Pulmonx.
What is the latest news on Pulmonx?
On Mar 05, 2026, SEC 8-K (1.01): On March 2, 2026, Pulmonx Corporation entered into a Credit Agreement and Guaranty with Perceptive Credit Holdings V, LP, establishing a senior secured term loan facility totaling up to $60.0 million. The Company initially borrowed $40.0 million on the closing date, with the potentia
Is Pulmonx a public company?
Yes. Pulmonx is publicly traded under the ticker LUNG.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy